The IP Future: Intellectual Property Challenges in AI Health Care Contracts

AI's Hidden Power Grid: Data Centers, Subsea Cables, and the New Infrastructure Arms Race

In this episode of The Good Bot, Brett Mason speaks with Alan Poole, general counsel of DC BLOX, about the physical backbone that makes AI possible: digital infrastructure. They explore how AI has turned infrastructure demand into a "space race," why subsea cable landing stations like Myrtle Beach are becoming strategic hubs, and how choosing sites hinges on power, land, and connectivity. The conversation also addresses community impacts, DC BLOX's transparency-first development model, and the emerging regulatory debate over who should pay for the massive grid upgrades needed to support AI-scale loads. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com [https://pcm.adswizz.com] for information about our collection and use of personal data for advertising.

Legal AI in Practice: Firm Governance, Build vs. Buy Decisions, and Vendor Due Diligence

In this episode of The Good Bot, Brett Mason sits down with Leigh Zeiser, director of AI and automation at Troutman Pepper Locke, to unpack how the firm operationalizes AI responsibly. They discuss the firm's AI portfolio — including Athena, the internal GPT-based chat agent — and the categories of tools used for research, drafting, eDiscovery, knowledge management, and workflow automation. The conversation covers the firm's evaluation framework and non‑negotiables (security, accuracy, fit for purpose, and contractual safeguards), the tradeoffs of building versus buying, and why human oversight and line‑by‑line accuracy testing remain essential. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com [https://pcm.adswizz.com] for information about our collection and use of personal data for advertising.

Navigating FDA's 2025 AI Guidance: Risk-Based Framework, Public Comments, and Generative Models

In this episode of The Good Bot, recorded in August of this year, Brett Mason welcomes FDA regulatory attorney Kyle Dolinsky to unpack the FDA's January 2025 draft guidance on artificial intelligence in drug and biologic development. They explain the agency's seven-step, risk-based framework for model planning, development, validation, and monitoring, and highlight practical takeaways such as early FDA engagement and documentation expectations. The conversation explores themes from public comments — including requests for more examples, clarity on generative and foundation models, and risks with third‑party AI — along with how administrative changes could shape the final document. The discussion analyzes comments and assesses their influence on the guidance and underscores that the FDA's approach is designed to enable responsible innovation, not restrict it. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com [https://pcm.adswizz.com] for information about our collection and use of personal data for advertising.

AI Underwriting Uncovered: Risks, Data, and Liability in Insurance

In this episode of The Good Bot, Brett Mason and Tom Kinney explore how artificial intelligence (AI) is reshaping the insurance and reinsurance industries. They discuss the rapid adoption of AI, the critical role of data management, and the unique risks insurers face as both enterprises and risk carriers.  Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com [https://pcm.adswizz.com] for information about our collection and use of personal data for advertising.

The IP Future: Intellectual Property Challenges in AI Health Care Contracts

In this episode of The Good Bot, Brett Mason is joined by Rusty Close, Austin Padgett, and Brent Hoard to explore the complexities of contracting for artificial intelligence (AI) in health care. The conversation points to key intellectual property concerns, including ownership of AI-generated content and the impact of recent Copyright Office guidance.  Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com [https://pcm.adswizz.com] for information about our collection and use of personal data for advertising.